Bevacizumab (CAS No. 216974-75-3), sold under the trade name Avastin, is a medication used to treat a number of types of cancers and a specific eye disease. For cancer it is given by slow injection into a vein and used for colon cancer, lung cancer, glioblastoma, and renal-cell carcinoma. Wikipedia
Effective March 8, 2019, the Office of Environmental Health Hazard Assessment (OEHHA) is adding Bevacizumab to the list of chemicals known to the state to cause reproductive toxicity (developmental and female endpoints), for purposes of Proposition 65.
The listing of bevacizumab is based on a formal requirement by the US Food and Drug Administration (FDA) that the chemical be identified or labeled as causing reproductive toxicity (developmental and female endpoints). The criteria for listing chemicals under the “formally required to be labeled or identified” mechanism are set out in Title 27, California Code of Regulations, section 25902.
The documentation supporting OEHHA’s determination that bevacizumab meets the criteria for listing is included in the Notice of Intent to List Bevacizumab posted on OEHHA’s website and published in the October 5, 2018 issue of the California Regulatory Notice Register (Register 2018, No. 40-Z). OEHHA received no public comments on the proposed listing.
A complete, updated chemical list is published in this issue of the California Regulatory Notice Register and is available on the OEHHA website at http://oehha.ca.gov/proposition-65/proposition-65-list.
CONTINUE READING ON oehha.ca.gov